Satish Marukurthi - CEO - Croissance
India has emerged as a strong base for clinical trial in recent times. Due to the multitude of benefits it offers, the country is fast growing as a center for conducting clinical trials. India has compelling need and keen aspirations for indigenous clinical research.
Conducting even one clinical trial is a monumental task with complex processes and issues that can surface and derail a study's timeline. The connection between sponsors and Contract Research Organization (CRO) is strengthening as outsourcing continues to be a clinical trial mainstay.
CROs' operational and technical capabilities have expanded as the pharmaceutical industry is undergoing profound changes with respect to regulatory requirements.
In this course of evolution and competition, Croissance Clinical Research has come into existence in the year of 2013. Over the last 4years, the company has gathered expertise in key therapeutic areas while remaining focused in Respiratory, Medical devices and Immunology studies.
Croissance has been successful in getting the trust by performing their activities with expected quality, timelines and cost effectiveness, which truly makes them to be a valuable extension of the Client's team.
With his vast experience of around two decades in the pharmaceutical industry at various levels, Mr. Satish Marukurthi formed the company and has been serving as CEO since then.
He is instrumental and playing an active role in development and growth of the Croissance. He is responsible for overseeing the business operations of the Croissance and is focused on stable growth, client satisfaction and long-term relationships.
His company Croissance has been supporting its clients in conducting phase trials which include II, III, IV, observational and Investigator Initiated Studies with focus on Clinical Operations, Data Management, Biostatistics, and Medical Writing.
Clients like Cipla Ltd., SUN Pharmaceutical Pvt. Ltd., Novo Nordisk India Private Ltd., Abbott India Ltd., Abbott Healthcare Pvt. Ltd, Bharat Biotech International Ltd., Biological E. Limited, Indian Immunologicals Ltd.,Biogen Idec,Bayer,ZydusPharma Private Limited, Pulse Pharmaceuticals have joined their hands with Croissance.
Croissance clinical study teams understand the importance of performing accurate feasibility to identify the desired sites and investigators to meet clients challenging expectations.
To accomplish this Croissance team has built a substantial internal database of sites across a broad range of indications and an investigator network of more than 6,000.
"We provide flexible and accurate data management solutions that ensure integrity, accuracy, reliability, cost effectiveness and speed. Our teams have extensive experience across various data management tools along with different clinical phases. Above all we believe in delivering in time and every time."
"Our journey was not a bed of roses, Croissance have passed through many footraces and our first project started with auditing a site. We have been providing many standalone services as well, and our first end to end project was worth of 80lakhs.
Irrespective of the size of the projects offered to us, our team has dedicatedly provided a quality service to all the clients," Croissance told The CEO Magazine.
This midsize clinical research organization (CRO) is providing a broad range of services in multiple geographic regions. The company has been successfully organizing Private, Govt. centers to conduct Clinical trial.
Croissance has successfully conducted clinical trials in the areas of Respiratory, Immunology, Endocrinology, Medical Devices, Ophthalmology, Cardiology, Oncology, Gynecology, Neurology, Pain, inflammation and Dermatology.
"We have the right people and broad-based expertise, with long standing therapeutic experience and a depth of clinical trial knowledge. Croissance experts can help you in making smarter decisions and more confident choices.
Our high percentage of repeat and referral business is proof that we have earned client confidence and loyalty. At Croissance we work together, we collaborate with every client to offer a tailored approach to fit the project needs," a spokesperson said.
Speaking to The CEO Magazine, Satish Marukurthi, CEO of Croissance Said "Our leading milestone in a short span of time has been to be a part of successful completion of a phase III trial and getting the marketing, manufacturing approval for the drug.
It is Croissance endeavor to become a reliable service provider globally for small and mid size pharmaceutical and biotech companies. Croissance Clinical Research's passion and drive for excellence are strong, and we are optimistic about the future of our company and the industry. We envision being a CRO with operations in US and Europe by 2018."
Croissance has a diverse, talented team of clinical development professionals who have been exceeding the Clients expectations.
Follow us on Google News